PCM
ESPR

Pentwater Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Pentwater Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-150,000
Closed -$3.17M – 251
2021
Q2 		$3.17M Buy
+150,000
New +$3.61M 0.03% 127
2019
Q1 		– Sell
-620,400
Closed -$28.5M – 150
2018
Q4 		$28.5M Sell
620,400
-479,600
-44% -$23.1M 0.24% 34
2018
Q3 		$48.8M Buy
1,100,000
+765,300
+229% +$35.1M 0.41% 26
2018
Q2 		$13.1M Buy
+334,700
New +$16.9M 0.1% 60
2017
Q2 		– Sell
-100,000
Closed -$3.53M – 107
2017
Q1 		$3.53M Buy
+100,000
New +$2.29M 0.04% 71

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Pentwater Capital Management's ESPR Position: Q4 2025 in Review

Pentwater Capital Management sold out of Esperion Therapeutics (ESPR) in Q4 2025, closing a stake of 181,290 shares — an estimated $480K sold.

Pentwater Capital Management first reported a position in ESPR in Q3 2013 and held it in 45 quarters. The position peaked at $167M in Q1 2018. 200 funds tracked by Wall St. Rank hold ESPR as of Q4 2025.

  • Pentwater Capital Management reported no remaining Esperion Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Pentwater Capital Management sold 181,290 Esperion Therapeutics shares in Q4 2025, an estimated $480K.
  • Pentwater Capital Management first reported a position in Esperion Therapeutics in Q3 2013 and held it in 45 quarters.
  • Pentwater Capital Management's Esperion Therapeutics position peaked at $167M in Q1 2018.
  • 200 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2025.

Based on Pentwater Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.